We have developed intellectual property in several early stage discoveries. Research on these is currently on hold while we invest in our more advanced development programmes.
VEGFR-3 (Vascular Endothelial Growth Factor Receptor 3 Kinase), also known at FLT4, is involved in the generation of new blood and lymph vessels to a tumour. It is often over produced in many different types of cancer including:
Lymph vessels are known to be a major route of metastasis. Inhibitors of VEGFR-3 therefore have the potential to reduce, delay or inhibit the spread of cancer throughout the body. We have discovered a series of compounds that demonstrate potent inhibition of lymph cell growth by selectively inhibiting VEGFR-3.
Cancer cells increase their consumption of sugars, fats and amino acids to satisfy the demands of continuous growth and multiplication. FASN, which controls the production of fatty acids, was first proposed as an anti-cancer target in 1994. FASN has been found to be over-produced in most types of solid tumour and has been linked to poor patient prognosis. Many cancer cell types can be destroyed by blocking FASN activity making it an attractive target for treating many types of cancer.
The exploration into our FASN research programme received £150,000 from the Technology Strategy Board. Programme compounds have demonstrated promising results in models of breast and colon cancer.
Anaplastic Lymphoma Kinase (ALK) is over active in Anaplastic Large Cell Lymphoma (ALCL, a type of non-Hodgkins Lymphoma), as well as certain lung cancers and childhood neuroblastomas. Sareum’s compounds, which were discovered from its SKIL platform, are potent against cancer cell types that have overactive ALK function.
Sareum has used its SKIL platform to develop a novel chemical series that inhibits the activity of FLT3 kinase and is highly selective against a panel of other kinases. These have potential use against certain types of leukaemia as well as autoimmune disorders such as Rheumatoid Arthritis and Multiple Sclerosis.
This programme arose from our SKIL library. Our lead compounds act in a similar way to the billion-dollar selling taxane class of cancer drugs. However, in contrast to taxanes, which are natural product derivatives, our Microtubule Binding Agents are entirely synthetic and can be dosed orally. They show significant potent activity against a range of colon, lung, breast & prostate cancer and leukaemia cell types.
Find out more by getting in touch at